Aluminium adjuvants - In retrospect and prospect

Vaccine

Volumn 22, Issue 27-28, 2004, Pages 3658-3668

  Lindblad, Erik B ^a  

^a Brenntag Biosector   (Denmark)

Author keywords

Aluminium; Anions; Diphtheria; Review

Indexed keywords

ALGAMMULIN; ALUMINUM DERIVATIVE; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; ALUMINUM SILICATE; ANTHRAX VACCINE; ANTIPARASITIC AGENT; ANTIPARASITIC VACCINE; BACTERIAL VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA VACCINE; FORMALDEHYDE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOGLOBULIN E; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LIPOPOLYSACCHARIDE; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; PROPIOLACTONE; SNAKE VENOM; TETANUS TOXOID; THIOMERSAL; TYPHOID VACCINE; UNCLASSIFIED DRUG; VACCINE; VIRUS VACCINE;

CARCINOGENICITY; DESENSITIZATION; DRUG HYPERSENSITIVITY; EDEMA; ERYTHEMA; HUMAN; IMMUNITY; LEUKOPENIA; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN INDURATION; SKIN NODULE; STEARATE ALUMINUM; TH2 CELL; VACCINATION;

EID: 4243187214     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.03.032     Document Type: Article

References (107)

1. Glenny A.T., Pope C.G., Waddington H., Wallace U. Immunological notes XVII to XXIV. J. Pathol. 29:1926;31-40
2. Glenny A.T., Buttle G.A.H., Stevens M.F. Rate of disappearance of diphtheria toxoid injected into rabbits and guinea-pigs: toxoid precipitated with alum. J. Pathol. 34:1931;267-275
3. Holt LB. Developments in diphtheria prophy1axis. London: Wm. Heinemann Ltd; 1950.
4. Maschmann E., Küster E., Fischer W. Über die Fähigkeit des Tonerde-Präparates B, Diphtherie-Toxin zu adsorbieren. Ber. Dtsch. Chem. Ges. 64:1931;2174-2178
5. Ericsson H. Purification and adsorption of diphtheria toxoid. Nature. 158:1946;350-351
6. Holt L.B. Purified precipitated diphtheria toxoid of constant composition. Lancet (i). 8:1947;282-285
7. Stewart-Tull DES. Recommandations for the assessment of adjuvants (immunomodulators). In: Gregoriadis G, Allison AC, Poste G, editors. Immunological adjuvants and vaccines. Plenum Publishing Corporation; 1989. p. 213-26.
8. Volk V.K., Bunney W.E. Diphtheria immunization with fluid toxoid and alum-precipitated toxoid. Am. J. Public Health. 32:1942;690-699
9. Kawamura Y., Sawai Y. Study on Indian Cobra Venom toxoid. Snake. 21:1989;6-8
10. Kawamura Y., Sawai Y. Study on the immunogenicity of purified toxoid of Siamese Cobra (Naja Naja kaouthia) Venom. Snake. 21:1989;81-84
11. Fujimaki H., Ozawa M., Imai T., Kubota K., Watanabe N. Adjuvant effects of aluminium silicate on IgE and Ig G1 antibody production in mice. Int. Archs. Allergy. Appl. Immun. 75(4):1984;351-356
12. Cooper P.D., McComb C., Steele E.J. The adjuvanticity of Algammulin, a new vaccine adjuvant. Vaccine. 9:1991;408-415
13. Woodhour A.F., Metzgar D.P., Stim T.P., Tytell A.A., Hilleman M.R. New metabolizable immunological adjuvant for human use. Development and animal immune response. Proc. Soc. Exp. Biol. Med. 116:1964;516-523
14. Hilleman M.R., Woodhour A.F., Friedman A., Phelps A.H. Studies for safety of Adjuvant 65. Ann. Allergy. 30:1972;477-483
15. Hem JE, Roberson CE. Chemistry of aluminium in natural water. form and stability of aluminium hydroxide complexes in dilute solution. US Geological Survey Water-Supply Paper 1827-A. Washington DC: US Government Printing Office; 1967.
16. 3. II. Mitteilung über Hydrate und Hydrogele. Ber. Dtsch. Chem. Ges. 56:1923;1117-1121
17. Willstätter R., Kraut H. Über die Hydroxide und ihre Hydrate in den verschiedenen Tonerde-Gelen. V. Mitteilung über Hydrate und Hydrogele. Ber. Dtsch. Chem. Ges. 57:1924;1082-1091
18. Nail S.L., White J.L., Hem S.L. Structure of aluminium hydroxide gel. Part I. Initial precipitate. J. Pharm. Sci. 65(8):1976;1188-1191
19. Hem S.L., White J.L. Characterization of aluminium hydroxide for use as an adjuvant in parenteral vaccines. J. Parent. Sci. Techn. 38(1):1984;2-11
20. Shirodkar S., Hutchinson R.L., Perry D.L., White J.L., Hem S.L. Aluminium compounds used as adjuvants in vaccines. Pharm. Res. 7(12):1990;1282-1288
21. Johnston C.F., Wang S.-L., Hem S.L. Measuring the surface area of aluminium hydroxide adjuvant. J. Pharm. Sci. 91(7):2002;1702-1706
22. Smith P.K., Krohn R.I., Hermanson G.T., Gartner F.H., Provenzano M.D., Fujimoto E.K., et al. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150:1985;76-85
23. Weeke B, Weeke E, Løwenstein H. The adsorption of serum proteins to aluminium hydroxide gel examined by means of quantitative immunoelectrophoresis. In: Axelsen NH, editor. Quantitative immunoelectrophoresis. New developments and applications. Universitetsforlaget; 1975. p. 149-54.
24. Lindblad EB. Aluminium adjuvants. In: Stewart-Tull, editor. The theory and practical application of adjuvants. New York: John Wiley & Sons; 1995. p. 21-35.
25. Relyveld EH, Raynaud M. In: Williams CA, Chase MW, editors. Methods in immunology and immunochemistry, vol. IV. Academic Press, New York; 1977. p. 283-93.
26. Thiele G.M., Rogers J., Collins M., Yasuda N., Smith D., McDonald T.L. An enzyme-linked immunosorbent assay for the detection of antitetanus toxoid antibody using aluminium-adsorbed coating antigen. J. Clin. Lab. Anal. 4:1990;126-129
27. Katz J.B., Hanson S.K., Patterson P.A., Stoll I.R. In vitro assessment of viral antigen content in inactivated aluminium hydroxide adjuvanted vaccines. J. Virol. Methods. 25:1989;101-108
28. May J.C., Progar J.J., Chin R. The aluminium content of biological products containing aluminium adjuvants: determination by atomic absorption spectrometry. J. Biol. Stand. 12:1984;175-183
29. Mannhalter J.W., Neychev H.O., Zlabinger G.J., Ahmad R., Eibl M.M. Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: Effect on antigen uptake and antigen presentation. Clin. Exp. Immunol. 61(1):1985;143-151
30. Dillon S.B., Demuth S.G., Schneider M.A., Weston C.B., Jones C.S., Young J.F., et al. Induction of protective class I MHC-restricted CTL in mice by a recombinant influenza vaccine in aluminium hydroxide adjuvant. Vaccine. 10(5):1992;309-318
31. Bomford R. The comparative selectivity of adjuvants for humoral and cell-mediated immunity. Part II. Effect on delayed-type hypersensitivity in the mouse and guinea pig, and cell-mediated immunity to tumour antigens in the mouse of Freund's incomplete and complete adjuvants, Alhydrogel, Corynebacterium parvum, Bordetella pertussis, muramyl dipeptide and saponin. Clin. exp. Immunol. 39:1980;435-441
32. Walls R.S. Eosinophil response to alum adjuvants: involvement of T cells in non-antigen-dependent mechanisms. Proc. Soc. Exp. Biol. Med. 156(3):1977;431-435
33. Sakata K.M., Tashiro K., Hirashima M., Hayashi H. Selective regulation of chemotactic lymphokine production. Part I. Selective potentiation of eosinophil chemotactic lymphokine production in alum hydroxy gel- and Bordetella pertussis vaccine-treated guinea-pigs. J. Immunol. 135(5):1985;3463-3467
34. Ramanathan V.D., Badenoch-Jones P., Turk J.L. Complement activation by aluminium and zirconium compounds. Immunology. 37:1979;881-888
35. Sagara T., Mori S., Ohkawara S., Goto F., Takagi K., Yoshinaga M. A limited role of IL-1 in immune-enhancement by adjuvants. Immunology. 71(2):1990;251-257
36. Grun J.L., Maurer P.H. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles. The role of endogenous interleukin-l in proliferative responses. Cell. Immunol. 121(1):1989;134-145
37. Mosmann T.R., Coffman R.L. TH 1 and TH 2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann. Rev. Immunol. 7:1989;145-173
38. Lindblad E.B., Elhay M.J., Silva R., Appelberg R., Andersen P. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect. Immun. 65(2):1997;623-629
39. Pollock K.G.J., Conacher M., Wei X.-Q., Alexander J., Brewer J.M. Interleukin-18 plays a role in both the alum-induced T helper 2 response and the T helper 1 response induced by alum-adsorbed interleukin-12. Immunology. 108:2003;137-143
40. Jankovic D., Caspar P., Zweig M., Garcia-Moll M., Showalter S.D., Vogel F.R., Sher A. Adsorption to aluminium hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp 120. J. Immunol. 163:1999;4481-4488
41. Brewer J.M., Conacher M., Satoskar A., Bluethmann H., Alexander J. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur. J. Immunol. 26:1996;2062-2066
42. Brewer J.M., Conacher M., Hunter C.A., Mohrs M., Brombacher J., Alexander J. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4 or IL-13-mediated signalling. J. Immunol. 163:1999;6448-6454
43. Bomford R., Aston R., Ivanyi J. Reversal of H-2-restricted hyporesponsiveness to human growth hormone by the use of aluminium hydroxide as adjuvant. Immunogenetics. 21:1985;505-509
44. Kenney J.S., Hughes B.W., Masada M.P., Allison A.C. Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies. J. Immunol. Meth. 121:1989;157-166
45. Hamaoka T., Katz D.H., Bloch K.J., Benacerraf B. Hapten-specific IgE antibody responses in mice. I. Secondary IgE response in irradiated recipients of syngeneic primed spleen cells. J. Exp. Med. 138:1973;306-311
46. Knopf P.M., Goldberg M., Grossi C.A., Cappello M., Coulter S.T. Induction of resistance to Schistosoma mansoni by immunization with subfractions of worms. Am. J. Trop. Med. Hyg. 38(3):1988;515-528
47. Horowitz S., Smolarsky M., Arnon R. Protection against Schistosoma mansoni achieved by immunization with sonicated parasite. Eur. J. Immunol. 12:1982;327-332
48. Uede T., Huff T.F., Ishizaka K. Formation of IgE binding factors by rat T lymphocytes. V. Effect of adjuvant for the priming immunization on the nature of Ig E binding factors formed by antigenic stimulation. J. Immunol. 129(4):1982;1384-1390
49. Uede T., Ishizaka K. Formation of IgE binding factors by rat T lymphocytes. VI. Cellular mechanisms for the formation of IgE-potentiating factor and IgE-suppressive factor by antigenic stimulation of antigen primed spleen cells. J. Immunol. 129(4):1982;1391-1397
50. Immunological Adjuvants. Technical Report Series 595. World Health Organization, Geneva; 1976.
51. McDougall J.S. Avian infectious bronchitis: the protection afforded by an inactivated virus vaccine. Vet. Rec. 85:1969;378-380
52. Wilson J.H.G., Hermann-Dekkers W.M., Leemans-Dessy S., de Meijer J.W. Experiments with an inactivated hepatitis leptospirosis vaccine in vaccination programmes for dogs. Vet. Rec. 100:1977;552-554
53. Sellers R.F., Herniman K.A.J. Early protection of pigs against foot-and-mouth disease. Br. Vet. J. 130:1974;440-445
54. Hyslop N.St.G., Morrow A.W. The Influence of aluminium hydroxide content, dose volume and the inclusion of saponin on the efficacy of inactivated foot-and-mouth disease vaccines. Res. Vet. Sci. 10(2):1969;109-120
55. Pini A., Danskin D., Coackley W. Comparative evaluation of the potency of beta-propiolactone inactivated Newcastle disease vaccines prepared from a lentogenic and a velogenic strain. Vet. Rec. 77(5):1965;127-129
56. Thorley C.M., Egerton J.R. Comparison of alum-adsorbed or non-alum-adsorbed oil emulsion vaccines containing, either pilate or non-pilate Bacteroides nodosus cells in inducing and maintaining resistance of sheep to experimental foot rot. Res. Vet. Sci. 30:1981;32-37
57. McCandlish I.A.P., Thompson H., Wright N.G. Vaccination against canine bordetellosis using an aluminium hydroxide adjuvant vaccine. Res. Vet. Sci. 25:1978;51-57
58. Nagy L.K., Penn C.W. Protective antigens in bovine pasteurellosis. Dev. Biol. Stand. 26:1974;65-76
59. Ris D.R., Hamel K.L. Leptospira interrogans serovar. pomona vaccines with different adjuvants in cattle. New Zealand Vet. J. 27:1979;169-171
60. Leland S.E., Sofield W.L., Minocha H.C. Immunogenic effects of culture-derived exoantigens of Cooperia punctata on calves before and after challenge exposure with infective larvae. Am. J. Vet. Res. 49(3):1988;366-379
61. Monroy F.G., Adams J.H., Dobson C., Bast I.J. Nematospiroides dubius: influence of adjuvants on immunity in mice vaccinated with antigens isolated by affinity chromatography from adult worms. Exp. Parasitol. 68(1):1989;67-73
62. Carlow C.K.S., Bianco A.E. Resistance of Onchocerca lienalis microfilariae in mice conferred by egg antigens of homologous and heterologous Onchocerca species. Parasitology. 94(3):1987;485-496
63. Gamble H.R., Murrell K.D., Marti H.P. Inocu1ation of pigs against Trichinella spiralis using larval excretory-secretory antigens. Am. J. Vet. Res. 47(11):1986;2396-2399
64. Randrup A. Physico-chemical and immunological studies on the virus of foot-and-mouth disease and its host tissue microsomes. Doctoral thesis. Munksgaard, Copenhagen; 1957.
65. Seeber S.J., White J.L., Hem S.L. Predicting the adsorption of proteins by aluminium-containing adjuvants. Vaccine. 9:1991;201-203
66. Rinella J.V., White J.L., Hem S.L. Effect of anions on model aluminium-adjuvant-containing vaccines. J. Colloid Interf. Sci. 172:1995;121-130
67. Rinella J.V., White J.L., Hem S.L. Effect of pH on the elution of model antigens from aluminium-containing adjuvants. J. Colloid Interface Sci. 205:1998;161-165
68. Rinella J.V., Workman R.F., Hermodson M.A., White J.L., Hem S.L. Elutability of proteins from aluminium-containing vaccine adjuvants by treatment with surfactants. J. Colloid Interface Sci. 197:1998;48-56
69. Levine L. A predictive equation for the primary immune response of mice to adsorbed tetanus toxoid as a function of dose of antigen and dose of adjuvant. J. Immunol. 109(5):1972;1138-1142
70. MacLennan R., Levine L., Newell K.W., Edsall G. The early primary immune response to adsorbed tetanus toxoid in man. Bull. WHO. 49:1973;615-626
71. Schmidt G. The adjuvant effect of aluminium hydroxide in influenza Vaccine. In: Symp. Series Immunobiol. Standard, vol. 6. New York: Karger, Basel; 1967.p. 275-82.
72. 3 as an immunological adjuvant. APMIS. 96:1988;257-284
73. Relyveld EH. In: Nistico G, Mastroeni P, Pitzurra M, editors. Proceedings of the Seventh International Conference on Tetanus. Roma: Gangemi Publ. Co.; 1985. p. 215-27.
74. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:2002;709-760
75. Ph. Eur. 3. Ed. Vaccines for human use; 1997. p. 1697.
76. Code of Federal Regulations 21, vol. 7: sec. 610.15 (Constituent Materials), revised April 1, 2003.
77. Martyn C.N., Barker D.J.P., Osmond C., Harris E.C., Edwardson J.A., Lacey R.F. Geographical relation between Alzheimers disease and aluminium in drinking water. Lancet. 1(8629):1989;59-62
78. 26Al Vaccine. 15:1997;1314-1318
79. Edelman R. Vaccine adjuvants. Rev. Infect. Dis. 2(3):1980;370-383
80. Aprile M.A., Wardlaw A.C. Aluminium compounds as adjuvants for vaccines and toxoids in man: a review. Can. J. Public Health. 57:1966;343-354
81. Collier LH, Polakoff S, Mortimer J, Reactions and antibody responses to reinforcing doses of adsorbed and plain tetanus vaccines. Lancet 1979:1364-7.
82. Butler N.R., Voyce M.A., Burland W.L., Hilton M.L. Advantages of aluminium hydroxide adsorbed combined diphtheria, tetanus, and pertussis vaccines for the immunization of infants. Brit. Med. J. 1:1969;663-666
83. Norimatsu M., Ogikubo Y., Aoki A., Takahashi T., Watanabe G., Taya K., et al. Effects of aluminium adjuvant on systemic reactions of lipopolysaccharides in swine. Vaccine. 13(14):1995;1325-1329
84. Shi Y., HogenEsch H., Regnier F.E., Hem S.L. Detoxification of endotoxin by aluminium hydroxide adjuvant. Vaccine. 19:2001;1747-1752
85. Böhler-Sommeregger K., Lindemayr H. Contact sensitivity to aluminium. Contact Dermat. 15:1986;278-281
86. Gupta R.K., Relyveld E.H., Lindblad E.B., Bizzini B., Ben-Efraim S., Gupta C.K. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine. 11(3):1993;293-306
87. Frost L., Johansen P., Pedersen S., Veien N., Østergaard P., Nielsen M. Persistent subcutaneous nodules in children hyposensitized with aluminium-containing allergen extracts. Allergy. 40:1985;368-372
88. Matzinger P. Tolerance, danger and the extended family. Ann. Rev. Immunol. 12:1994;991-1045
89. Batista A, Lindblad EB, Analyzing toxicological aspects of immunological adjuvants for vaccine and experimental use, 2003, submitted for publication.
90. Chaby R, Caroff M, Lipopolysaccharides of Bordetella pertussis endotoxin. in: Wardlaw AC, Parton P, editors. Pathogenesis and immunity in pertussis. New York: Wiley; 1988. p. 247-71.
91. 4 on purified influenza virus hemagglutinins in man. J. Immunol. 100(5):1968;1139-1140
92. Cvjetanovic B., Uemura K. The present status of field and laboratory studies of typhoid and paratyphoid vaccines. Bull. WHO. 32:1965;29-36
93. Francis M.J., Fry C.M., Rowlands D.J., Bittle J.L., Houghten R.A., Lerner R.A., et al. Immune response to uncoupled peptides of foot-and-mouth disease virus. Immunology. 61:1987;1-6
94. Bomford R, Aluminium salts: perspectives in their use as adjuvants. In: Gregoriadis G, Allison AC, Poste G, editors. Immunological adjuvants and vaccines. Plenum Publishing Corp.; 1989. p. 35-41.
95. Francis M.J., Fry C.M., Rowlands D.J., Brown F., Bittle J.L., Houghten R.A., et al. Immunological priming with synthetic peptides of foot-and-mouth disease virus. J. Gen. Vir. 66:1985;2347-2354
96. Lew A.M., Anders R.F., Edwards S.J., Langford C.J. Comparison of antibody avidity and titre elicited by peptide as a protein conjugate or as expressed in vaccinia. Immunology. 65(2):1988;311-314
97. Geerligs H.J., Weijer W.J., Welling G.W., Welling-Wester S. The influence of different adjuvants on the immune response to a synthetic peptide comprising amino acid residues 9-21 of herpes simplex virus Type 1. J. Immunol. Meth. 124(1):1989;95-102
98. Goldenthal KL, Cavagnaro JA, Alving C, Vogel FR, Safety evaluation of vaccine adjuvants. NCVDG Working Groups. AIDS Res. Human Retroviruses 1993;9(Suppl 1):s47-51.
99. Talwar G.P., Singh O., Singh V., Rao D.N., Sharma N.C., Das C., et al. Enhancement of anti-gonadotropin response to the beta-subunit of ovine luteinizing hormone by carrier conjugation and combination with the beta-subunit of human chorionic gonadotropin. Fertil. Steril. 46(1):1986;120-126
100. Mahi-Brown C.A., Yanagimachi R., Hoffman J.C., Huang T.T.F. Fertility control in the bitch by active immunization with porcine Zonae Pellucidae. Use of different adjuvants and patterns of estradio1 and progesterone levels in estrous cycles. Biol. Reprod. 32(4):1985;761-772
101. Montgomery V.A., Makuch R.S., Brown J.E., Hack D.C. The immunogenicity in humans of a botulinum type F vaccine. Vaccine. 18(7-8):1999;728-735
102. Fiock M.A., Cardella M.A., Gearinger N.F. Studies on immunity to toxins of Clostridium botulinum, IX. Immunologic response of man to purified pentavalent ABCDE botulinum toxoid. J. Immunol. 90:1963;697-702
103. Ulmer J.B., DeWitt C.M., Chastain M., Friedman A., Donelly J.J., McClements W.L., et al. Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine. 18:2000;18-28
104. Kwissa M, Lindblad EB, Schirmbeck R, Reimann J. Co-delivery of a DNA vaccine and a protein vaccine with aluminium phosphate stimulates a potent and multivalent immune response. J Mol Med 2003;81:502-10.
105. Nomura F., Akashi S., Sakao Y., Sato S., Kawai T., Matsumoto M., et al. Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface Toll-like receptor 4 expression. J. Immunol. 164(7):2000;3476-3479
106. Ashkar A.A., Rosenthal K.L. Toll-like receptor 9, CpG DNA and innate immunity. Curr. Mol. Med. 2(6):2002;545-556
107. Sun H., Pollock K.G.J., Brewer J.M. Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine. 21:2003;849-855